Menu Search
Equities

Candel Therapeutics Inc

CADL:NMQ

Candel Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.14
  • Today's Change0.16 / 4.02%
  • Shares traded444.98k
  • 1 Year change+354.80%
  • Beta-0.9609
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Candel Therapeutics Inc's revenues fell -100.00% from 125.00k to 0.00. has fallen 101.87% from a loss of 18.79m to a larger loss of 37.94m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-145.85%
Return on equity-1,344.47%
Return on investment-227.04%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Candel Therapeutics Inc fell by 34.65m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 34.24m for operations while cash used for investing totalled 280.00k.
Cash flow per share-1.71
Price/Cash flow per share--
Book value per share-0.4749
Tangible book value per share-0.4749
More ▼

Balance sheet in USDView more

Candel Therapeutics Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio1.18
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.